Targeting co-stimulatory molecules in autoimmune disease
NM Edner, G Carlesso, JS Rush… - Nature Reviews Drug …, 2020 - nature.com
Therapeutic targeting of immune checkpoints has garnered significant attention in the area
of cancer immunotherapy, in which efforts have focused in particular on cytotoxic T …
of cancer immunotherapy, in which efforts have focused in particular on cytotoxic T …
[HTML][HTML] Rationale for anti-OX40 cancer immunotherapy
S Aspeslagh, S Postel-Vinay, S Rusakiewicz… - European Journal of …, 2016 - Elsevier
Immune checkpoint blockade with antagonistic monoclonal antibodies (mAbs) targeting B7
immunoglobulin superfamily molecules (CTLA-4, PD-1, and PD-L1) generate long lasting …
immunoglobulin superfamily molecules (CTLA-4, PD-1, and PD-L1) generate long lasting …
Eradication of spontaneous malignancy by local immunotherapy
It has recently become apparent that the immune system can cure cancer. In some of these
strategies, the antigen targets are preidentified and therapies are custom-made against …
strategies, the antigen targets are preidentified and therapies are custom-made against …
[HTML][HTML] Therapeutic strategies for the costimulatory molecule OX40 in T-cell-mediated immunity
Y Fu, Q Lin, Z Zhang, L Zhang - Acta Pharmaceutica Sinica B, 2020 - Elsevier
The T cell co-stimulatory molecule OX40 and its cognate ligand OX40L have attracted broad
research interest as a therapeutic target in T cell-mediated diseases. Accumulating …
research interest as a therapeutic target in T cell-mediated diseases. Accumulating …
The significance of OX40 and OX40L to T‐cell biology and immune disease
OX40 (CD134) and its binding partner, OX40L (CD252), are members of the tumor necrosis
factor receptor/tumor necrosis factor superfamily and are expressed on activated CD4+ and …
factor receptor/tumor necrosis factor superfamily and are expressed on activated CD4+ and …
OX40 agonists and combination immunotherapy: putting the pedal to the metal
SN Linch, MJ McNamara, WL Redmond - Frontiers in oncology, 2015 - frontiersin.org
Recent studies have highlighted the therapeutic efficacy of immunotherapy, a class of
cancer treatments that utilize the patient's own immune system to destroy cancerous cells …
cancer treatments that utilize the patient's own immune system to destroy cancerous cells …
Control of immunity by the TNFR-related molecule OX40 (CD134)
M Croft - Annual review of immunology, 2009 - annualreviews.org
TNFR/TNF superfamily members can control diverse aspects of immune function. Research
over the past 10 years has shown that one of the most important and prominent interactions …
over the past 10 years has shown that one of the most important and prominent interactions …
[HTML][HTML] AXL targeting restores PD-1 blockade sensitivity of STK11/LKB1 mutant NSCLC through expansion of TCF1+ CD8 T cells
Mutations in STK11/LKB1 in non-small cell lung cancer (NSCLC) are associated with poor
patient responses to immune checkpoint blockade (ICB), and introduction of a Stk11/Lkb1 …
patient responses to immune checkpoint blockade (ICB), and introduction of a Stk11/Lkb1 …
The landscape of immunotherapy in advanced NSCLC: Driving beyond PD-1/PD-L1 inhibitors (CTLA-4, LAG3, IDO, OX40, TIGIT, vaccines)
A De Giglio, A Di Federico, G Nuvola, C Deiana… - Current oncology …, 2021 - Springer
Abstract Purpose of Review In this review, we analyzed the current landscape of non-PD-(L)
1 targeting immunotherapy. Recent Findings The advent of immunotherapy has completely …
1 targeting immunotherapy. Recent Findings The advent of immunotherapy has completely …
OX40 triggering blocks suppression by regulatory T cells and facilitates tumor rejection
S Piconese, B Valzasina, MP Colombo - The Journal of experimental …, 2008 - rupress.org
Regulatory T (T reg) cells are the major obstacle to cancer immunotherapy, and their
depletion promptly induces conversion of peripheral precursors into T reg cells. We show …
depletion promptly induces conversion of peripheral precursors into T reg cells. We show …